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Background: Rheumatoid arthritis (RA) is a severe chronic immune mediated inflammatory disease that has been
shown to be associated with human leukocyte antigen (HLA) loci. The transporter associated with antigen processing 2
(TAP2) has been identified to play an important role in the HLA-associated diseases and immune response. The goal of
our meta-analysis was to summarize the contribution of TAP2 polymorphisms to the risk of RA.
Methods: Meta-analyses were performed between RA and 3 TAP2 coding polymorphisms that comprised
TAP2-379Ile > Val (rs1800454), TAP2-565Ala > Thr (rs2228396) and TAP2-665Thr > Ala (rs241447). The meta-analyses
were involved with 9 studies (24 individual studies) among 973 cases and 965 controls.
Results: Meta-analyses showed that TAP2-379Ile allele was significantly associated with an increased risk of RA
(p = 0.0002, odds ratio (OR) = 1.44, 95% confidence interval (CI) = 1.18-1.74). This association was further shown only in the
dominant model (p = 0.006, OR = 1.59, 95% CI = 1.14-2.22). Subgroup analyses by ethnicity revealed that the association of
TAP2-379Ile was significant in Asians (p = 0.03, OR = 1.38, 95% CI = 1.04-1.83). In addition, another significant association of
TAP2-565Thr allele with RA was observed in Europeans (p = 0.002, OR = 1.62, 95% CI = 1.20-2.20).
Conclusions: Our meta-analyses suggested that TAP2-379Ile allele was significantly associated with a 59% increased risk
in the dominant effect model. Subgroup analyses by ethnicity showed that TAP2-379-Ile increased the risk of RA
by 38% in Asians and TAP2-565Thr increased the risk of RA by 38% in Europeans.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2097080313124700
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Rheumatoid arthritis (RA) is a common immune-mediated
chronic inflammatory disease [1]. Severe clinical symptoms
of RA comprise bone lose [2] and heart diseases [3] that
can make a huge destruction to human body. RA is a
complex disease caused by both genetic and environmental
factors. Twin studies estimated a large heritability (60%) in
RA [4]. Family-based studies also demonstrated that genetic
factors played a more important role in the development of
RA than environmental factors [5,6].* Correspondence: duanshiwei@nbu.edu.cn
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unless otherwise stated.Consistent association was found between human leu-
kocyte antigen (HLA) loci and RA [7]. The transporter
associated with antigen processing 2 (TAP2) gene encodes
transporter 2, ATP-binding cassette, sub-family B (MDR/
TAP) that is a major histocompatibility complex (MHC)
gene located between HLA-DP and HLA-DQ [8]. TAP2
delivers antigenic peptides to the endoplasmic reticulum
of HLA class I molecular [9], especially in selecting the
size of peptides [10]. TAP2 has been shown to play an
important role in the HLA-associated diseases and
immune response [11].
TAP2 polymorphisms have been tested for their associ-
ation with the occurrence and development of RA [12-23].
Among them, Ile379Val, Ala565Thr and Thr665Ala are. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Nomenclature of TAP2 haplotypes
TAP2 TAP2-379 TAP2-565 TAP2-665
GTA ATA GTA ATA GTA ATA
A Val Ala Thr
B Val Ala Ala
C Ile Ala Thr
D Ile Thr Thr
E Val Thr Thr
F Val Ala Thr
G Ile Ala Ala
H Ile Thr Ala
Val: Valine; Ile: Isoleucine; Ala: Alanine; Thr: Threonine.
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case–control studies for the TAP2 polymorphisms with
RA, yielding only 2 significant results (Table 1). We
suspected that a lack of power in the previous studies
with moderate sample size might influence the reliability
of the results [24]. Meta-analysis is often used to enhance
statistical power and thus is likely to produce a more
convincing conclusion [25]. Here we performed a set of
meta-analyses of the three polymorphisms by pooling
up the data from individual association study [25]. Our
research is likely to provide a better evaluation of the
contribution of TAP2 polymorphisms to the risk of RA.
Methods
We collected studies that examined the associations of
TAP2 polymorphisms with RA in September of 2013 by
searching the online databases (PubMed, WanFang, WeiPu
and CNKI) without time and language restriction, using
the keywords “rheumatoid arthritis TAP2 association” and
“rheumatoid arthritis TAP2 polymorphism”. The obtainedTable 1 Characteristics of the case–control studies in the curr
Gene locus First author Year Country Ethnicity Geno
meth
TAP2-379 B. P. Wordsworth [14] 1993 Britain Europeans ARMS
Sara Marsal [15] 1994 America Europeans ARMS
M.C. Hillarby [16] 1996 Britain Europeans ARMS
F. Takeuchi [17] 1997 Japan Asians PCR-R
J Vinasco [18] 1998 Spain Europeans PCR-R
Sasijit Vejbaesya [19] 2000 Thailand Asians ARMS
S.-L. Zhang [20] 2002 France Europeans ARMS
Min-Chien Yu [21] 2004 China Asians PCR-R
TAP2-565 B. P. Wordsworth [14] 1993 Britain Europeans ARMS
Sara Marsal [15] 1994 America Europeans ARMS
M.C. Hillarby [16] 1996 Britain Europeans ARMS
F. Takeuchi [17] 1997 Japan Asians PCR-R
J Vinasco [18] 1998 Spain Europeans PCR-R
S.-L. Zhang [20] 2002 France Europeans ARMS
Min-Chien Yu [21] 2004 China Asians PCR-R
Yu L [22] 2013 China Asians PCR-R
TAP2-665 B. P. Wordsworth [14] 1993 Britain Europeans ARMS
Sara Marsal [15] 1994 America Europeans ARMS
M.C. Hillarby [16] 1996 Britain Europeans ARMS
F. Takeuchi [17] 1997 Japan Asians PCR-R
J Vinasco [18] 1998 Spain Europeans PCR-R
Juha Tuokko [23] 1998 Finland Europeans PCR-R
S.-L. Zhang [20] 2002 France European ARMS
Min-Chien Yu [21] 2004 China Asians PCR-R
ARMS-PCR: Amplification refractory mutation system; PCR-RFLP: Polymerase Chain R
Hardy-Weinberg equilibrium; Result*, The association between IL1B gene and PD; N
is TAP2-665Ala.studies would be included in our meta-analyses if they
met the following criteria: (1) It was an original case–con-
trol study with an assessment of the association of TAP2
with RA in humans; (2) It contains sufficient information





Control source HWE Result* Pοwer MAF
-PCR 60/117 Population NA NS 0.101 0.167
-PCR 185/48 Population NA NS 0.086 0.177
-PCR 89/64 Population NA S 0.091 0.172
FLP 92/95 Population NA NS 0.095 0.132
FLP 50/55 Population NA NS 0.072 0.109
-PCR 82/100 Population Yes NS 0.115 0.220
-PCR 138/100 Population Yes NS 0.098 0.120
FLP 100/99 Population Yes NS 0.124 0.237
-PCR 60/117 Population NA NS 0.094 0.132
-PCR 185/48 Population NA NS 0.081 0.156
-PCR 89/64 Population NA NS 0.086 0.148
FLP 92/95 Population NA S 0.09 0.116
FLP 50/55 Population NA NS 0.059 0.036
-PCR 138/100 Population Yes S 0.078 0.070
FLP 100/99 Population Yes NS 0.086 0.096
FLP 177/288 Population Yes NS 0.169 0.142
-PCR 60/117 Population NA NS 0.115 0.248
-PCR 185/48 Population NA NS 0.084 0.167
-PCR 89/64 Population NA NS 0.119 0.375
FLP 92/95 Population NA NS 0.136 0.347
FLP 50/55 Population NA NS 0.091 0.264
FLP 40/60 Population No NS 0.095 0.350
-PCR 138/100 Population Yes NS 0.148 0.300
FLP 100/99 Population Yes NS 0.147 0.601*
eaction –Restriction Fragment Length Polymorphism; HWE.
S, No significant; S, Significant; NA: Not applicable; *The reference allele
Figure 1 Flowchart of selection process in the meta-analyses.
Dai et al. Diagnostic Pathology 2014, 9:129 Page 3 of 7
http://www.diagnosticpathology.org/content/9/1/129(95% CIs); (3) Genotype distribution of each polymorphism
in controls met Hardy-Weinberg equilibrium (HWE); (4)
The cumulative number of individual studies for one
genetic locus are at least three. We extracted or calculated
the following information from each selected study: the first
author, year of publication, country, ethnicity, genotypingTable 3 Meta-analyses of TAP2-379, TAP2-565, TAP2-665with
Genetic locus Cases/controls (S*) Genetic model
TAP2-379 796/677 (8) Overall ( I vs V)
522/768 (5)
274/293 (3)
320/298 (3) Dominant ( II/IV vs VV )
320/298 (3) Recessive ( II vs IV/VV )
198/209 (3) Additive ( II vs VV )
TAP2-565 891/871 (8) Overall ( T vs A )
522/778 (5)
369/482 (3)
415/487 (3) Dominant ( TT/TA vs AA )
415/487 (3) Recessive ( TT vs TA/AA )
335/384 (3) Additive ( TT vs AA )
TAP2-665 714/578 (7) Overall ( A vs T )
522/384 (5)
192/194 (2)
238/199 (2) Dominant ( AA/AT vs TT )
238/199 (2) Recessive ( AA vs AT/TT )
128/100 (2) Additive ( AA vs TT )
S*: Amount of stages; V: Valine; I: Isoleucine; A: Alanine; T: Threonine.method, numbers of cases and controls, control source,
HWE for controls, reported association results, power of
each involved study and minor allele frequency (MAF) in
each stage.
Since some studies presented the data of haplotypes
(A to H, Table 2), our study translated the haplotypes intoRA*
Ethnicity OR (95% CI) P value I2 Power
Overall 1.44 (1.18-1.74) 0.0002 42% 0.477
Europeans 1.39 (0.88-2.20) 0.16 64% 0.286
Asians 1.38 (1.04-1.83) 0.03 0% 0.241
1.59 (1.14-2.22) 0.006 0% 0.336
1.24 (0.58-2.64) 0.58 0% 0.104
1.49 (0.68-3.23) 0.32 0% 0.101
Overall 1.23 (0.84-1.81) 0.28 64% 0.439
Europeans 1.62 (1.20-2.20) 0.002 24% 0.229
Asians 0.87 (0.43-1.75) 0.70 76% 0.254
1.17 (0.85-1.61) 0.33 45% 0.379
4.71 (0.51-43.33) 0.17 64% 0.075
4.64 (0.52-41.77) 0.17 64% 0.075
Overall 1.02 (0.85-1.22) 0.84 48% 0.557
Europeans 0.87 (0.69-1.09) 0.23 39% 0.475
Asians 1.32 (0.99-1.77) 0.06 0% 0.080
1.07 (0.44-2.57) 0.88 67% 0.252
0.58 (0.06-5.77) 0.64 77% 0.131
1.15 (0.53-2.49) 0.73 83% 0.122
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TAP2-565, and TAP2-665) [8,26]. We used Arlequin pro-
gram [27] to test whether the genotyping distribution
in controls was in HWE. Cochran’s Q statistic and I2
test [28] were used to calculate statistical heterogeneity.
Fixed-effect model would be used to the studies with
minimal to moderate heterogeneity (I2 < 50%), and the
random-effect model would be used to the studies with
significant heterogeneity (I2 > =50%). Combined ORs and
CIs were estimated by Review Manager 5 [29]. Funnel
plots were drawn to observe the potential publication
bias. The power of each study was calculated by Power
and Sample Size Calculation program. All the statistical
analyses were performed by two independent reviewers
(Ping Ru and Xingyu Zhou).
Results and discussion
As shown in Figure 1, 22 genetic studies on TAP2 gene
were initially collected. Of them, we excluded 7 studiesFigure 2 Forest plots of TAP2 gene polymorphisms with RA. A: Forest
TAP-379 with RA in Asians; C: Forest plot of TAP-379 with RA under dominathat were not related to RA, 1 case-only study, 4 studies
without genotyping information, 1 study that did not
meet HWE. Finally, 9 articles [14-22] were involved in the
current study. Altogether, there were 973 RA patients and
965 controls in the meta-analyses of 3 TAP2 polymor-
phisms (Tables 1 and 3).
In the present study, we tested the associations between
3 TAP2 polymorphisms and RA disease. Different inherit-
able models, including dominant, recessive and additive
models, were also tested for all 3 polymorphisms. As
shown in Table 3 and Figure 2, a significant association
of TAP2-379Ile with increased risk of RA was found
for combined population (p = 0.0002, OR = 1.40, 95%
CI = 1.16-1.70). Subgroup analysis by ethnicity showed
that this significant association was only found in Asians
(p = 0.03, OR = 1.38, 95% CI = 1.04-1.83, Table 3 and
Figure 2) but not in Europeans (p = 0.16, Table 3). In
addition, significant contribution of TAP2-379Ile to RA was
only found in the dominant model (p = 0.006, OR = 1.59,plot of TAP-379 with RA for combined population; B: Forest plot of
nt effect model; D: Forest plot of TAP-565 with RA in Europeans.
Figure 3 Funnel plots of TAP2 gene polymorphisms with RA.
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there was no significant result in the combined populations
(p = 0.28, Table 3), but we found significant association
between Europeans and RA (p = 0.002, OR = 1.62, 95%
CI = 1.20-2.20, Table 3, Figure 2). For TAP2-665 locus, no
significant result was found in the combined meta-analyses
or in the subgroup meta-analyses (Table 3).
Significant statistical heterogeneity was found in the
meta-analyses of TAP2-565 (I2 = 64%). A further subgroup
meta-analyses by ethnicity showed that significant hetero-
geneity was coming from the Europeans for TAP2-379
(I2 = 64%) and Asians for TAP2-565 (I2 = 76%). Further
subgroup studies showed that significant heterogeneity
also existed in the meta-analyses of TAP2-565 (recessive
model: I2 = 64%; additive model: I2 = 64%) and TAP2-665
(dominant model: I2 = 67%, recessive model: I2 = 77%;
additive model: I2 = 83%).
All the power analyses in current meta-analyses were
tested under a moderate risk of SCZ (OR = 1.2, Tables 1
and 2). Compared with previous individual studies, our
meta-analyses showed a much stronger power (Tables 1
and 3). In addition, no publication bias for the meta-
analyses was observed (Figure 3).
To our knowledge, our study was the first meta-analyses
of the three coding polymorphisms of TAP2 gene. Previ-
ous studies showed significant association between TAP2
gene and autoimmune diseases such as allergic rhinitis
[30], systemic lupus erythematosus [31] and RA [20,21].
Our results indicated that TAP2-379Ile was able to
increase 44% of the risk of RA in all subjects and 38%
of the risk of RA in Asians. Moreover, TAP2-379Ile was
associated with a 59% increased risk of RA in the
dominant model. We also found that TAP2-565Thr
increased the risk of RA by 62% in Europeans.
Previous RA association studies observed a handful of
single nucleotide polymorphisms (SNPs) with dominant
effect such as -607A/C polymorphism of IL-18 gene [32],
rs10489629 of IL-23R gene [33], −173G/C polymorphism
of MIF gene [34] and -607A/C polymorphism of IL-18
gene [32]. Our observation of significant association of
TAP2-379Ile polymorphism in the dominant model sup-
ported that dominant model might be a key genetic model
in the pathogenesis of RA disease.
Since MAFs are different in different populations,
we further evaluated the role of TAP2 polymorphisms
in Asians and Europeans separately. For TAP2-379Ile,
significant association was found in Asians but not in
Europeans. On the contrary, we observed TAP2-565Thr
as a risky factor of RA in Europeans but not in Asians.
This might be due to a lack of power in the subgroup
meta-analysis in Europeans for TAP2-379 (power = 0.286,
I2 = 64%) and in Asians for TAP2-565 (power = 0.254,
I2 = 76%). To be noted, one Asian study [21] involved
in the meta-analyses of TAP2-665Ala was found a highallele frequency (allele frequency = 0.601, Table 1) than
those in the rest studies (average allele frequency = 0.284).
Our meta-analyses presented several limitations that
needed to be taken with cautions. Firstly, the associations
of TAP2 polymorphisms were only evaluated in Europeans
and Asians. The findings might not be feasible for other
populations such as Africans. And potential difference in
intra-European and intra-Asian population might influence
the result of our study (see the MAFs in Table 1). Secondly,
RA is a complex chronic disease. Different clinical variables
may influence the results of the current study. Hidden
physiological factors may exist in the RA patients and affect
the quality of the current meta-analysis. Further studies
with precise diagnosis might be helpful for a better meta-
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current meta-analyses was much stronger than the previous
studies, more replicated studies are required to strengthen
the stability of the association between TAP2 polymor-
phisms and RA. Fourthly, certain multiple testing existed
in the current study, and cautions needed to be taken
for the significant results. Fifthly, there are 2232 poly-
morphisms in TAP2 gene according to the NCBI dbSNP
database. Our study only focused on three polymorphisms
of TAP2 that might be hard to give fully consideration of
the contribution of TAP2 polymorphisms. Moreover, the 3
TAP2 polymorphisms might not be the causal variants but
be in high linkage disequilibrium with other established
RA MHC variants. Sixthly, since significant associations
were found in the both allelic and dominant model for
TAP2-379, our results implied the genetic models of
TAP2-379 polymorphism were complex and hard to be
determined. Seventhly, there were publication biases for the
current meta-analyses of TAP2-379 and TAP2-565. After
removing the outlier studies [16,17], the results of the two
meta-analyes remained the same as the previous one.
Conclusions
In summary, our meta-analyses suggested that TAP2-
379Ile allele was significantly associated with a 59%
increased risk in the dominant model. To be more specif-
ically, TAP2-379-Ile increased the risk of RA by 38% in
Asians and TAP2-565Thr increased the risk of RA by 38%
in Europeans. Future large-scale and well designed studies
are required to confirm our findings and to reveal other
TAP2 polymorphisms with contribution to RA disease.
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